Among holdings in which CalSTRS increased its stake were MannKind (NASDAQ: MNKD  ) and Keryx Biopharmaceuticals (NASDAQ: KERX  ) . Biotech concern MannKind has seen its shares nearly triple in value over the past year, with investors hopeful that its inhaled insulin product Afrezza will receive FDA approval soon. The stock has enormous potential, but also significant risk, with approval and strong sales not yet in place. And a lot of success is already built into the stock's recent price, leaving less upside.
http://www.passfail.com/news/ipo-news/heres-what-this-30-billion-pension-fund-has-been-buying-motley-fool/heres-what-this-30-billion-pension-fund-has-been-buying-motley-fool-10353742.htm